Clene (CLNN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, with voting available online or in person until May 20, 2026.
Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.
Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 annual meeting: Robert Etherington, Shalom Jacobovitz, and Alison H. Mosca.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
Advisory approval of compensation for Named Executive Officers.
Approval of an amendment to the Amended 2020 Stock Plan to increase reserved shares by 1,000,000.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Latest events from Clene
- Net loss widened to $13.4M in Q2 2026, with ongoing funding concerns and rising R&D costs.CLNN
Q2 2026 - NDA filing for a novel ALS therapy is planned for early Q4, supported by new biomarker data.CLNN
Canaccord Genuity's 46th Annual Growth Conference - FDA meeting and NDA filing for ALS therapy targeted in 2024, with strong survival data presented.CLNN
Emerging Growth Virtual Conference - FDA supports NDA submission for ALS drug based on neurofilament reduction; MS phase III planned.CLNN
Emerging Growth Conference 92 - Net loss was $8.1M in Q1 2026; NDA for CNM-Au8 in ALS planned for Q3 2026.CLNN
Q1 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and stock plan expansion.CLNN
Proxy filing - Net loss narrowed in 2025, with strong financing and positive ALS biomarker data supporting NDA plans.CLNN
Q4 2025 - CNM-Au8 significantly reduced ALS biomarkers and improved survival, supporting accelerated approval.CLNN
Study Update - Significant clinical progress and regulatory milestones expected for nanotherapeutics in ALS and MS.CLNN
Q2 Virtual Investor Summit Event